



## DEPARTMENT OF HEALTH &amp; HUMAN SERVICES

Food and Drug Administration  
Rockville MD 20857

August 11, 2000

Thank you for your letter of July 20, 2000 regarding dimercapto propane sulfonate (DMPS).

In your letter, you enclosed a MedWatch report that describes the adverse events that you have associated with the use of DMPS. I will forward your report to the MedWatch office so that this information can be entered into our database.

In addition, I will forward your letter and a redacted version of your MedWatch report to our docket management branch for inclusion into the public docket for pharmacy compounding (Docket #98D-0272).

Thank you for providing us with this important information. If I can provide any future assistance, I hope you will not hesitate to contact me.

Sincerely,

Jane Axelrad

Associate Director for Policy  
Center for Drug Evaluation and Research  
Food and Drug Administration

98D-0272

ANS 1